Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 8 of 24 pages ‹ First < 6 7 8 9 10 > Last ›
HSL6748
Baraldi R.
Drug company money: to accept or not to accept? Is that the question
DES Action Canada Newsletter 1997; (51):1-2, 4-6
www.web.net/~desact
HSL6759
The internet and drugs
Health Horizons 1997; (32):2
www.ifpma.rog/hhhs/welcome.htm
HSL6761
Unethical promotion of Hepavar
The Network’s Newsletter 1997; 6:(5):2
HSL8196
Wright M.
Prescription drug availability in Australia following the Baume Report
International Journal of Pharmaceutical Medicine 1997; 11:(1):19-22
HSL8197
Harrison HE.
Legal aspects of pharmaceutical medicine
International Journal of Pharmaceutical Medicine 1997; 11:(1):42-46
HSL8223
Penna RP.
Leadership and complex issues
American Journal of Pharmaceutical Education 1997; 61:(3):322-323
HSL8322
Skutnik S, Katsanis LP.
Impact of initial noncompliance in Canadian retail pharmacies: descriptive examination
Journal of Pharmaceutical Marketing Management 1997; 11:(4):35-54
HSL9048
Danzon P.
Pharmaceutical Price Regulation: National Policies versus Global Interests
Washington, DC: American Enterprise Institute 1997
http://www.aei.org/books/bookID.190,filter.all/book_detail.asp
HSL18033
Blondeel L
Evidence based advertising? Avertisement for nifedipine does not mention admitted shortcomings of study.
BMJ 1997; 315:(7122):1621
http://www.bmj.com/cgi/content/full/315/7122/1621?view=long&pmid=9437299
HSL19867
Towards a New Strategy
Health Horizons 1997; 33:
HSL622
Holm S, Evans M.
Product names, proper claims? More ethical issues in the marketing of drugs.
BMJ 1996 Dec 21-28; 313:(7029):1627-9
http://www.bmj.com/cgi/content/full/313/7072/1627
HSL18034
de Craen AJ, Roos PJ, Leonard de Vries A, Kleijnen J.
Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness.
BMJ 1996 Dec 21-28; 313:(7072):1624-6
http://www.bmj.com/cgi/content/full/313/7072/1624?view=long&pmid=8991013
HSL20466
Ed.
Betraying the public over nvCJD risk
The Lancet 1996 Dec 7; 348:(9041):1592
http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2896%2921049-9/fulltext
HSL6629
Blumenthal D, Campbell EG, Causino N, Louis KS.
Participation of life-science faculty in research relationships with industry.
N Engl J Med 1996 Dec 5; 335:(23):1734-9
http://content.nejm.org/cgi/content/abstract/335/23/1734
HSL592
Strang D, Gagnon M, Molloy W, Bedard M, Darzins P, Etchells E, Davidson W.
National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives.
Ann R Coll Physicians Surg Can 1996 Dec; 29:(8):474-8
HSL602
Pritchard MS.
Conflicts of interest: conceptual and normative issues.
Acad Med 1996 Dec; 71:(12):1305-13
HSL617
Kodish E, Murray T, Whitehouse P.
Conflict of interest in university-industry research relationships: realities, politics, and values.
Acad Med 1996 Dec; 71:(12):1287-90
HSL628
Frankel MS.
Perception, reality, and the political context of conflict of interest in university-industry relationships.
Acad Med 1996 Dec; 71:(12):1297-304
HSL6628
Blumenthal D.
Ethics issues in academic-industry relationships in the life sciences: the continuing debate.
Acad Med 1996 Dec; 71:(12):1291-6
HSL6708
Searle Canada, the Arthritis Society and the Canadian Rheumatology Association: innovative health education web site launched
PMAC News 1996 Dec; 21-22
www.canadapharma.org
HSL6709
Mansfield P, Vitry A.
Re: the promotion of Nitro-Dur (glyeryl trinitrate)
1996 Dec;
HSL6710
Rhein RW.
Law enforcement and the Internet superhighwaymen
Scrip Magazine 1996 Dec; (52):18-20, 22
www.pjbpubs.co.uk/scrip/scrhome.html
HSL8239
Gaunt R, Whitfield M, Ghalamkari H, Millar M.
General practitioner prescribing and community pharmacist recommendation for the sale of aciclovir topical cream
International Journal of Pharmacy Practice 1996 Dec; 4:204-208
HSL8337
Monaghan MJ, Monaghan MS.
Do market components account for higher US prescription prices?
Ann Pharmacother 1996 Dec; 30:(12):1489-94
HSL9139
Gerrard L.
Clinical trials workload in a teaching (university) hospital
ASHP Midyear Clinical Meeting 1996 Dec; 31:
HSL621
Horton R.
Prizes, publications, and promotion.
Lancet 1996 Nov 23; 348:(9039):1398
HSL638
Angel JE.
Drug advertisements and prescribing.
Lancet 1996 Nov 23; 348:(9039):1452-3
HSL20536
Blutstein H
Dealing Drugs Legally
The Big Issue 1996 Nov 1714-16
HSL584
Wise P, Drury M.
Pharmaceutical trials in general practice: the first 100 protocols: An audit by the clinical research ethics committee of the Royal College of General Practitioners.
BMJ 1996 Nov 16; 313:(7067):1245-8
http://www.bmj.com/cgi/content/full/313/7067/1245
HSL8243
Mason P.
Gastrointestinal disease: has reclassification of GI drugs changed the treatment of disease?
Pharmaceutical Journal 1996 Nov 16; 257:731-732
HSL20174
Wiseman H
Riding a gift-horse: the risks
Australian Doctor 1996 Nov 1521
HSL590
Tan LB.
The politics of disclosure.
Lancet 1996 Nov 9; 348:(9037):1314-5
HSL8331
Vehse W.
Medicinal products: restrictions on distribution
Pharmaceutisch Weekblad 1996 Nov 8; 131:1299-1301
HSL596
Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P.
Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario.
CMAJ 1996 Nov 1; 155:(9):1243-
HSL613
Lal A, Moharana AK, Chandra P, Ray A.
Critical evaluation of references in drug advertisements: an Indian experience.
J Assoc Physicians India 1996 Nov; 44:(11):778-9
HSL6704
Schwartz H.
Boom times for the drug detailer?—the Schwartz view
Scrip Magazine 1996 Nov; (51):29-30
www.pjbpubs.co.uk/scrip/scrhome.htm
HSL6707
Promotion of glyceryl trinitrate transdermal patches
MaLAM Australian News 1996 Nov-Dec; 4:(11-12):1-2
HSL8236
Pleaner D.
Current issues affecting community pharmacy practice. Part 2
South African Pharmaceutical Journal 1996 Nov-Dec; 63:452
HSL8342
Cacciatore GG.
Advertising, computers, and pharmacy liability: A Michigan court's decision has ramifications for pharmaceutical care
Journal of the American Pharmaceutical Association 1996 11; 36:651-654
HSL6702
Zinberg DS.
Morality Play [response]
Science 1996 Oct 27; 273:1786-1787?
HSL19807
McNamee D
Different kind of drug-company freebie
The Lancet 1996 Oct 19; 348:(9034):1048
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2805%2964413-3/fulltext
HSL19901
Bonati M, Forte GB, de Joncheere K, Magnusson E
Drug donations to Bosnia-Hercegovina are often inappropriate
BMJ 1996 Oct 19; 313:(7063):1011
HSL632
Dikshit RK, Dikshit N.
What information is available on request from drug advertisers in India?
BMJ 1996 Oct 5; 313:(7061):855-6
http://www.bmj.com/cgi/content/full/313/7061/855
HSL20019
Tiner R
Pharmaceutical representatives: Guidelines exist on making effective use of time spent with representatives
BMJ 1996 Oct 5; 313:881
http://www.bmj.com/content/313/7061/881.2
HSL20020
Ferner RE
Pharmaceutical representatives: Doctors should decline to see them
BMJ 1996 Oct 5; 313:881
http://www.bmj.com/content/313/7061/881.3
HSL20021
Breimer L
Advertisements in the BMJ: Advertisements for drugs used in disorders with a negative image never feature men.
BMJ 1996 Oct 5; 313:(7061):883
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359056/
HSL579
Angell M, Kassirer JP.
Editorials and conflicts of interest.
N Engl J Med 1996 Oct 3; 335:(14):1055-6
HSL607
Manson JE, Faich GA.
Conflicts of interest--editorialists respond.
N Engl J Med 1996 Oct 3; 335:(14):1064-5
HSL583
Wolfe SM.
Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? Characteristics of materials distributed by drug companies: four points of view
J Gen Intern Med. 1996 Oct 01; 11:(10):637-9
HSL589
Temple R, O'Brien P.
Why would anyone have expected anything else?Characteristics of materials distributed by drug companies: four points of view.
J Gen Intern Med. 1996 Oct 01; 11:(10):640-1
HSL611
Landefeld CS, Chren MM.
Drug companies and information about drugs: recommendations for doctors. Characteristics of materials distributed by drug companies: four points of view
J Gen Intern Med 1996 Oct 01; 11:(10):642-4
HSL2034
Stryer D, Bero LA.
Characteristics of materials distributed by drug companies. An evaluation of appropriateness.
J Gen Intern Med 1996 Oct; 11:(10):575-83
HSL2097
Fleming TR, DeMets DL.
Surrogate end points in clinical trials: are we being misled?
Ann Intern Med 1996 Oct 1; 125:(7):605-13
http://www.annals.org/cgi/content/full/125/7/605
HSL6692
PMAC marketing code: CHE provisions under review
PMAC News 1996 Oct; 7-8
HSL6693
Lexchin J, Vitry A.
Re: the promotion of Smecta (smectite)
1996 Oct;
HSL6694
Mansfield P.
Campaign to combat misleading promotion
INRUD News 1996 Oct; 6:(2):3
HSL6695
Talbot-montgomery E.
Seizing the opportunities for direct-to-consumer promotion
Scrip Magazine 1996 Oct; (49):45-47
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6703
Knowledge is the best medicine campaign: a “new vision” for PMAC’s education program
PMAC News 1996 Oct; 8
HSL8328
Koberstein W.
What patients want: industry responds
Pharmaceutical Executive 1996 Oct; 16:80-82, 84, 86, 88, 90, 92, 94,
HSL8330
Weschsler J.
Headway on the Hill
Pharmaceutical Executive 1996 Oct; 16:20, 24, 26
HSL9159
Shefcheck SL, Thomas J 3rd.
The outlook for pharmacist initiation and modification of drug therapy.
J Am Pharm Assoc (Wash) 1996 Oct; NS36:(10):597-604
HSL20424
Bless H, Schwarz N, Clore GL, Golisano V, Rabe C, Wölk M.
Mood and the use of scripts: does a happy mood really lead to mindlessness?
J Pers Soc Psychol 1996 Oct; 71:(4):665-79
http://psycnet.apa.org/journals/psp/71/4/665/
HSL20464
Day M
Secrecy destroys faith in drug safety
New Scientist 1996 Sep 284
http://www.newscientist.com/article/mg15120490.200-secrecy-destroys-faith-in-drug-safety.html
HSL6697
Benet LZ.
Morality play.
Science 1996 Sep 27; 273:(5283):1782
HSL6698
Debler WR.
Morality play.
Science 1996 Sep 27; 273:(5283):1783
HSL6699
Eckert C.
Morality play.
Science 1996 Sep 27; 273:(5283):1784
HSL6700
Hook EB.
Morality play.
Science 1996 Sep 27; 273:(5283):1784
HSL6701
Thomen JR.
Morality play.
Science 1996 Sep 27; 273:(5283):1783-4
HSL20463
Ed.
Secrets about drugs are not healthy
Lancet 1996 Sep 21; 348:(9030):765
http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2805%2965201-4/fulltext
HSL605
Myers MG.
"Drug may have caused huge number of deaths": lessons learned during an encounter with The Fifth Estate.
CMAJ 1996 Sep 15; 155:(6):772-5
HSL9138
Curtiss FR.
Drug formularies provide a path to best care.
Am J Health Syst Pharm 1996 Sep 15; 53:(18):2201-3
HSL582
Wolfe S.
Drug advertisements that go straight to the hippocampus.
Lancet 1996 Sep 7; 348:(9028):632
HSL20012
Robbins T
GPs tell reps how to sell their products
Australian Doctor 1996 Sep 624
HSL612
Lal A, Sethi A.
Drug package inserts in India.
Ann Pharmacother 1996 Sep; 30:(9):1041
HSL6696
The impact of drug promotion on drug expenditure
MaLAM Australian News 1996 Sep-Oct; 4:(9-10):1-4
HSL8338
Fahey M.
Guide to consumers' pharmaceutical purchasing behavior
Journal of Managed Care Pharmacy 1996 Sep-Oct; 2:489-490, 494, 498-499
HSL8339
Wechsler J.
MedGuide missteps, AIDS advances, and pharma prices
Managed Healthcare 1996 Sep; 6:
HSL8346
Timetable, targets proposed for prescription information program
Consultant Pharmacist 1996 Sep; 11:958
HSL15302
Gill PS, Freemantle N, Bero L, Haaijer-Ruskamp F, Markela M, Barjesteh KP.
GPs' prescribing behaviour may be affected by drug promotion.
BMJ 1996 Aug 10; 313:(7053):367
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=8760769
HSL20325
Gill PS, Freemantle N, Bero L, Haaijer-Ruskamp F, Markela M, Barjesteh KP
GP's prescribing behaviour may be affected by drug promotion
BMJ 1996 Aug 10; 313:(367):
http://www.bmj.com/content/313/7053/367.2
HSL20465
Meredith B
Informing patients about the drugs they take
BMJ 1996 Aug 10; 313:
http://www.bmj.com/content/313/7053/315
HSL6620
Baird PA.
Funding medical and health-related research in the public interest.
CMAJ 1996 Aug 1; 155:(3):299-301
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=8705910
HSL6690
The Arthritis Society and Pfizer Canada Inc. in joint education effort
PMAC News 1996 Aug; 8
HSL6691
PMAC president questions Canadians’ access to prescription drug information
PMAC News 1996 Aug; 4-5
HSL8340
Rankin K.
Mission: alliances
Drug Store News for the Pharmacist 1996 Aug; 6:15-16, 18, 21
HSL8917
Newton G, Popovich NG, Pray WS.
Rx-to-OTC switches: from prescription to self-care.
J Am Pharm Assoc (Wash) 1996 Aug; NS36:(8):488-95
HSL16730
Wolfe S
Current FDA
The Journal of NIH Research 'Reform' Would Endanger Americans 1996 Aug; 8:37-8
HSL6689
Zinberg DS.
A cautionary tale.
Science 1996 Jul 26; 273:(5274):411
http://www.sciencemag.org/cgi/reprint/273/5274/411
HSL16729
Wolfe S
Perspective on Public Health: Save the Gold Standard
The LA Times 1996 July 22
HSL608
Macbeth F, Stephens R.
Marketing clinical trials.
Lancet 1996 Jul 13; 348:(9020):111-2
HSL20372
Bloor K, Maynard A, Freemantle N
Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.
BMJ 1996 July 6; 313:(7048):33-35
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2351415/
HSL597
Rothermich EA, Pathak DS, Smeenk DA.
Health-related quality-of-life claims in prescription drug advertisements.
Am J Health Syst Pharm 1996 Jul 1; 53:(13):1565-9
HSL633
Dean M.
Guidelines for CME need revamping.
Can Fam Physician 1996 Jul; 42:1295-7:
HSL6681
Re: the promotion of Ponstan (mefenamic acid)
MaLAM disagrees with the conclusion of the IFPMA regarding the complaint about the advertising of Ponstan (mefenamic acid) in Pakistan. 1996 Jul;
HSL6682
Mansfield P, Vitry A.
Re: the promotion of Nitro-Dur (glyceryl trinitrate)
1996 Jul;
HSL6683
Mansfield P, Vitry A.
Re: the promotion of Transderm-Nitro (glyeryl trinitrate)
1996 Jul;
HSL6684
Bayer claims that “nifedipine significantly reduces the incidence of cardiovascular events”
MaLAM Australian News 1996 Jul-Aug; 4:(7-8):2
HSL6685
MaLAM letter follow up—IFPMA rulings: “Unsurpassed” dishonesty
MaLAM International News 1996 Jul-Aug; 14:(7-8):1-2
HSL6686
Philippine ad wars over pain killers
Drug Monitor 1996 Jul-Aug; 11:(4):29-31
HSL6687
Schering-Plough claims patients should not “fear rebound” with Nitro-Dur and Ciba-Geigy claims Transderm-Nitro has “benefits beyond angina prevention”
MaLAM Australian News 1996 Jul-Aug; 4:(7-8):1-2
Page 8 of 24 pages ‹ First < 6 7 8 9 10 > Last ›
